Board of Directors

  • Amir Belson, M.D.
    • was the founder of Neoguide Systems, that was acquired by Intuitive Surgical in 2009, Vascular Pathways, a vascular intervention technology which was acquired by C R Bard, Zipline Medical, a wound closure technology company, Qool Therapeutics, a minimally invasive therapeutic hypothermia technology company, Radiaction Medical, a radiation protection medical device company, VasoStitch, which develops large vessel access and closure technology, Emboline, which develops proprietary embolic protection technology, Modular Surgical which develops new minimally invasive surgery technology, Oxyvive, a chronic/diabetic wound care technology company and SuperRenal which develops a technology to prevent contrast nephropathy and to extend the time until the start of renal replacement therapy in CRF patients.

      Dr. Belson also serves as board director of Alter-G, Relometrics and QT Vascular.

      Belson graduated cum laude from the school of medicine of the Technion, Israel Institute of Technology, in Haifa, Israel. He did his pediatric residency at Dana Children’s Hospital in Tel Aviv and his pediatric nephrology fellowship at Lucile Packard Children’s Hospital at Stanford University. Belson also spent one year as a research fellow with the Biomedical Technology Innovation Program at Stanford.

      He is the author of 34 medical papers and abstracts and has more than 400 issued and pending patents.   

       

  • Gregory D. Casciaro
    Executive Chairman of Apama Medical
    • is currently Chief Executive Officer and President at Cardiac Dimensions, Inc., a medical device company developing products to treat heart failure. He has been a Director of Apama Medical a medical device company in the Atrial Fibrillation sector since December 2014. Greg serves as a director with Dextera Surgical Inc, (DXTR) since December 2014 and serves as a director of QT Vascular Ltd., a medical device company, since 2001. Prior to QT Vascular, Mr. Casciaro served as the President and Chief Executive Officer of AccessClosure, Inc., a medical device company that was acquired by Cardinal Health, Inc. Prior to joining AccessClosure, he was the president, CEO and a director of XTENT, Inc., a medical device company that was acquired by Biosensors International Group, Ltd. Previously, Mr. Casciaro served as the President, Chief Executive Officer and a director of Orquest Inc., a private company manufacturing and selling bio-therapeutic products to the orthopedic market. Mr. Casciaro previously served as a director of AngioDynamics, Inc. and Kerberos Proximal Solutions. He was president, Chief Executive Officer and a director at General Surgical Innovations, Inc., a laparoscopic surgical equipment manufacturer that was acquired by United States Surgical, a division of Tyco Healthcare Group, and held executive and management positions at Vascular Intervention, a division of Guidant Corporation, North American Instrument Corporation, and Procter & Gamble Co. Mr. Casciaro graduated from Marquette University with a B.A. in Business Administration.

  • Sho Kian Hin, Eric
    • is an independent director and the audit committee chairman of QT Vascular Ltd., a company listed on the Catalist of the Singapore Exchange Securities Trading Limited. As a fellow member of The Association of Certified Chartered Accountants (ACCA), he started off his professional training with Victors & Company in 1990 and joined Ernst & Young Kuala Lumpur in 1995. He left Ernst & Young Kuala Lumpur as Assurance & Advisory Business Services Manager in 2002, to join the private sector and in 2007, became the Executive Director and Chief Financial Officer of China Farm Equipment Ltd, a company then listed on the Main Board of the Singapore Exchange Securities Trading Limited, where he was responsible for, amongst others, planning and management of the group’s financial and taxation matters, acted as key liaison person with the stock exchange, supervised compliance with corporate governance, and handled investors’ relationship, regional roadshows as well as funding options for the group. China Farm Equipment Ltd was privatised in 2013, and Eric remains involved in the ongoing corporate exercise to list the assets in PRC.

  • Eitan Konstantino, PhD
    CEO, Co-Founder
    • Prior to leading QT Vascular Ltd., Dr. Konstantino founded TriReme Medical, LLC and Quattro Vascular Pte Ltd. Dr. Konstantino was co-founder, President and Chief Scientist of AngioScore, Inc from its inception until 2007. Dr. Konstantino is the primary inventor of the AngioSculpt catheter and the Easy Exchange delivery system. Previously, Dr. Konstantino was the CEO & COO of Advanced Stent Technologies (“AST”), a bifurcation stent company that was acquired by Boston Scientific in 2004. He co-invented the Petal bifurcation stent that is currently with Boston Scientific. Prior to AST, he was Chief Technical Officer of Bypass Ltd, a developer of nitinol anastomotic devices for minimally invasive heart surgery. Dr. Konstantino is co-founder of Singapore Medtech Accelerator (“SMA”), an appointed Biomedical Science Accelerator (“BSA”) under the Singapore Government’s Research, Innovation and Enterprise 2015 plan. Dr. Konstantino is also an appointed member of Singapore’s government SPRING Medtech Network of Advisors.

      Dr. Konstantino received his PhD from Technion – Israel Institute of Technology.

  • Gary Ng
    • was appointed to our Board on 6 August 2015. He is the Company’s Director of Strategy and Capital Markets since February 2015. Gary has over 14 years of experience as an equity analyst with Solomon Smith Barney, Deustche Bank and CIMB with primary focus on healthcare. During his time as an equity analyst, Gary was involved in various fundraising activities for capital market deals and is a ranked analyst in various broker polls such as Asiamoney Brokers Poll and Thomson Reuters StarMine Analyst Awards. Gary graduated from University of London with a Bachelor of Business.

  • Mark A. Wan
    Founding Partner of Three Arch Partners
    • Mark Wan is a founding partner of Causeway Media Partners. He is also a founding partner of Three Arch Partners. Prior to cofounding Three Arch Partners, Mr. Wan was a general partner at Brentwood Associates. Since starting in venture capital in 1987, Mr. Wan has emphasized working with entrepreneurs in early stage companies. He has often assumed temporary operating responsibility, managing key functions during a company’s young life. He has served on the boards of many private and public companies. Mr. Wan holds a BS in Engineering from Yale University. He also holds an MBA from the Stanford Graduate School of Business.